Capricor Therapeutics, Inc. (CAPR) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

7/25

Growth 1 Margin 1 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

7
Capricor Therapeutics (CAPR) Q2 2026: $42.9M Operating Expense Reflects Strategic Investment Amid Regulatory Uncertainty
August 17, 2026
8
Capricor Therapeutics (CAPR) Q1 2026: $36.8M Operating Expense Signals Full-Scale Launch Readiness Amid NS Pharma Standoff
May 13, 2026
9
Capricor Therapeutics (CAPR) Q4 2025: HOPE III Data Drives 91% Cardiomyopathy Progression Slowdown, Readying for Transformational Launch
March 13, 2026
8
Capricor Therapeutics (CAPR) Q3 2025: R&D Spend Rises 65% as HOPE III Phase III Data Nears Pivotal FDA Decision
November 11, 2025
7
Capricorn Therapeutics (CAPR) Q2 2025: R&D Spend Up 72% as FDA Path for Daromyosil Remains Unclear
August 13, 2025
9
Capricorn Therapeutics (CAPR) Q1 2025: R&D Spend Jumps 60% as BLA Approval Path Intensifies
July 06, 2025
9
Capricor Therapeutics (CAPR) Q4 2024: $152M Cash Position Fuels Transition to Commercial Stage Amid FDA Priority Review
March 19, 2025
Capricor (CAPR) Q3 2024: $1.5B Milestone Path as Daromyosel BLA Filing Targets 8,000-Patient Cardiac Market
November 13, 2024
Capricor Therapeutics (CAPR) Q2 2024: $700M Milestone Path Anchored by BLA Acceleration and Cardiac Label Expansion
August 07, 2024
Capricor Therapeutics (CAPR) Q1 2024: $10M Milestone Payment Accelerates BLA Path for CAP-1002
May 13, 2024
Capricor Therapeutics (CAPR) Q4 2023: $10M Milestone Payment Signals Accelerated BLA Path for CAP-1002
February 29, 2024

Browse all companies